Clinical trial
Topotecan Plus Sargramostim in Treating Patients With Advanced Cancer
NCT00002950 · Yale University, Other · Completed
Key facts
| NCT number | NCT00002950 |
|---|---|
| Title | Topotecan Plus Sargramostim in Treating Patients With Advanced Cancer |
| Official title | Phase I/II Study of Topotecan (SKF 104864) With Recombinant GM-CSF (Sargramostim) Used as a Priming Agent in Advanced Malignancies |
| Lead sponsor | Yale University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Biological, Drug |
| Interventions | sargramostim, topotecan hydrochloride |
| Enrollment | 25 |
| Start date | Sep 26, 1996 |
| Primary completion | Feb 10, 2002 |
| Completion | Feb 10, 2002 |
| First posted | Mar 26, 2004 |
| Last update posted | Aug 17, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: